Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1041-1049

  Tural, Deniz ^a   Batur, Sebnem ^b   Erdamar, Sibel ^b   Akar, Emre ^b   Kepil, Nuray ^b   Mandel, Nil Molinas ^b   Serdengeçti, Süheyla ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

BRAF; Colorectal cancer; KRAS; Outcome; PI3K; PTEN

Indexed keywords

B RAF KINASE; CETUXIMAB; IRINOTECAN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PREDICTIVE VALUE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, PHARMACOLOGICAL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; ELAFIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PTEN PHOSPHOHYDROLASE; RAS PROTEINS;

EID: 84899115294     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1138-8     Document Type: Article

References (20)

1. Jemal A, Siegel R,Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2009;59:225-49.
2. Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metastases. Oncologist. 2008;13:1063-73.
3. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-17.
4. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45. (Pubitemid 38944402)
5. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160-74.
6. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27:663-71.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-65.
8. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, et al. Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 2008;9:962-72.
9. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-8. (Pubitemid 46548951)
10. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-12.
11. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009;20:84-90.
12. FrattiniM, Saletti P, Romagnani E,MartinV,Molinari F,Ghisletta M, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007;97:1139-45. (Pubitemid 47587019)
13. Loupakis F, Pollina L, Stasi I, Ruzzo A, ScartozziM, Santini D, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol. 2009;27:2622-9.
14. Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R. Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas. Am J Clin Pathol. 2005;124:392-401. (Pubitemid 41232925)
15. Zhu YF, Yu BH, Li DL, Ke HL, Guo XZ, Xiao XY. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol. 2012;18:3745-51.
16. Saridaki Z, TzardiM, Papadaki C, SfakianakiM, Pega F, Kalikaki A, et al. Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥2 line cetuximab-based therapy of colorectal cancer patients. PLoS One. 2011;20(6):15980-92.
17. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2012;23:1518-25.
18. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010: 11753-62.
19. Prenen H, De Schutter J, Jacobs B, De Roock W, Biesmans B, Claes B, et al. PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res. 2009;15:3184-8.
20. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254-61.